Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) comprises several clinical entities with diverse clinical presentations, outcomes, and nonunifying pathogenesis. AAV has a clear potential for relapses, and shows unpredictable response to treatment. Cyclophosphamide-based therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Lenert, Aleksander, Lenert, Petar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4294650/
https://www.ncbi.nlm.nih.gov/pubmed/25609919
http://dx.doi.org/10.2147/DDDT.S67264

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4294650/
https://www.ncbi.nlm.nih.gov/pubmed/25609919
http://dx.doi.org/10.2147/DDDT.S67264

Ejemplares similares